Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission is a research paper published in Cancers (2023). On theSindex it has a DataRank of 0.457. It has been cited 20 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.457
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: P30 CA008748
National Institutes of Health
Grant: P01 CA190174
National Institutes of Health
Grant: U24 CA224319
National Institutes of Health
Grant: U01 DK124165
National Institutes of Health
Grant: P30 CA196521
National Institutes of Health
Grant: 5U01DK124165-02
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 5U24CA224319-04
High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials
National Institutes of Health
Grant: 3P01CA190174-04S1
Immunologic Approaches to Ovarian Cancer
National Institutes of Health
Grant: 1P30CA196521-01
Mouse Genetics
FWCI
1.84
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals